The drug manufacturing giant Sanofi-Aventis together with the Columbia University Medical Center is all set to develop drugs for diabetes. It is supposed to be a three year alliance. It shall be with the Gerard Karsenty for the investigation of the role of Osteocalcin in the issue of diabetes management.

In the research, they revealed that those cells that form bones in the body are also responsible for the production of Osteocalcin. This is the hormone that is responsible for the production of blood sugar levels and the deposition of fat in the body.

According to the spokesperson at Sanofi, “"The findings have opened the door for an entirely new area of exploration for novel pathways, targets and therapies directed toward metabolic disorders, including diabetes".

As per the terms and condition of the three year pact, Sanofi shall have an access to the technological aspects and research station of Vision Institute. The major areas of concern for them are going to be vascular biology, gene therapy, optical nerve, and inflammation in various types’ tissues of the eyes.

“The collaboration will encourage the sharing of technical expertise and know-how with the objective to deliver innovative therapies for people with visual impairment and supports our ambition to build a global offer in ophthalmology”, said Christopher Viehbacher, the Chief Executive of Sanofi.